COUR is a clinical-stage biotechnology company working to reprogram the immune system to restore health in people suffering from autoimmune diseases. Using our proprietary COUR nanoparticle (CNP) platform for antigen-specific immune tolerance, we develop first-in-class disease-modifying therapies that target disease at its root—without suppressing normal immune system function. With programs in primary biliary cholangitis (PBC), type 1 diabetes (T1D), myasthenia gravis (MG), and celiac disease, COUR is advancing a new standard for immune-modifying therapies.
Company Details
- Employees
- 80
- Founded
- -
- Address
- 8025 Lamon Ave, Skokie,illinois 60077,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://courpharma.com
- HQ
- Skokie, Illinois
Cour Pharma Questions
Cour Pharma's website is http://courpharma.com
Cour Pharma's LinkedIn profile is https://www.linkedin.com/company/courpharma
Cour Pharma has
80 employees.
View email and phone details for 80
employees at Cour Pharma.
Cour Pharma's industry is
Pharmaceutical Manufacturing
Cour Pharma's top competitors are
Gilgamesh Pharmaceuticals,
Fauna Bio,
Profound Therapeutics,
Abdera Therapeutics,
Nodthera,
Excision Biotherapeutics,
Recludix Pharma,
Tubulis Gmbh,
Bighat Biosciences,
Ascidian Therapeutics.
Cour Pharma's categories are Pharmaceutical Manufacturing
Cour Pharma's founding year is 2015
